Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082688 | 0.89 | TRPV1 (0.73) | TRPV1NPC1RAB9AHDAC1 | |
| SCHEMBL14082633 | 0.85 | TRPV1 (0.65) | TRPV1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL26215401 | 0.85 | SCN2A (0.50) | MEN1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL5934533 | 0.84 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL14082636 | 0.84 | TRPV1 (0.66) | TRPV1POLBNPC1RAB9AHDAC1 | |
| SCHEMBL14082629 | 0.84 | TRPV1 (0.70) | TRPV1POLBNPC1RAB9AMAPT | |
| SCHEMBL14082475 | 0.83 | MMP2 (0.59) | POLBMITFMEN1NPC1RAB9A | |
| SCHEMBL11972898 | 0.82 | RAB9A (0.68) | TRPV1POLBMITFMEN1NPC1 | |
| SCHEMBL13428706 | 0.82 | RAB9A (0.68) | TRPV1POLBMITFMEN1NPC1 | |
| SCHEMBL28954009 | 0.82 | MAPT (0.53) | POLBMITFMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885POLB 4543/4885MITF 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.